Successful switch to rilpivirine/tenofovir/emtricitabine in HIV‐1‐infected patients with an isolated K103N mutation acquired during prior nonnucleoside reverse transcriptase inhibitor therapy

• Published in: HIV medicine 2014-11, Vol.15 (10), p.611-614
• Main Authors: Rokx, C, Verbon, A, Rijnders, BJA
• Format: Article
• Language: English
• Subjects: Adenine - analogs & derivatives; Adenine - therapeutic use; Adult; Anti-HIV Agents - therapeutic use; antiretroviral therapy; Deoxycytidine - analogs & derivatives; Deoxycytidine - therapeutic use; drug resistance; Drug Resistance, Viral - genetics; Drug Substitution; Emtricitabine; Female; HIV Infections - drug therapy; HIV Infections - virology; HIV-1 - drug effects; HIV-1 - genetics; HIV‐1; Humans; Male; Mutation; Nitriles - therapeutic use; Organophosphonates - therapeutic use; Pilot Projects; Prospective Studies; Pyrimidines - therapeutic use; Reverse Transcriptase Inhibitors - therapeutic use; Rilpivirine; single tablet regimen; Tenofovir; Viral Load; Young Adult
• ISSN: 1464-2662; 1468-1293
• DOI: 10.1111/hiv.12157

Objectives Whether treatment‐experienced HIV‐1‐infected patients with an acquired K103N mutation after failing nonnucleoside reverse transcriptase inhibitor (NNRTI) regimens can be treated with rilpivirine is unknown. The aim of this pilot study was to evaluate the efficacy of rilpivirine/tenofovir/emtricitabine in HIV‐1‐infected patients with an isolated K103N mutation. Methods A prospective study was carried out in HIV‐1‐infected adults who acquired the K103N mutation on failing NNRTI regimens. No other mutations in reverse transcriptase were allowed. Patients had to be on second‐line regimens with HIV‐1 RNA